Jiangsu Kanion Pharmaceutical Co.,Ltd.

Shanghai Stock Exchange 600557.SS

Jiangsu Kanion Pharmaceutical Co.,Ltd. Price to Earnings Ratio (P/E) on January 27, 2025: 13.97

Jiangsu Kanion Pharmaceutical Co.,Ltd. Price to Earnings Ratio (P/E) is 13.97 on January 27, 2025, a -26.30% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Jiangsu Kanion Pharmaceutical Co.,Ltd. 52-week high Price to Earnings Ratio (P/E) is 25.45 on March 18, 2024, which is 82.08% above the current Price to Earnings Ratio (P/E).
Jiangsu Kanion Pharmaceutical Co.,Ltd. 52-week low Price to Earnings Ratio (P/E) is 13.06 on September 18, 2024, which is -6.55% below the current Price to Earnings Ratio (P/E).
Jiangsu Kanion Pharmaceutical Co.,Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is 17.07.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Shanghai Stock Exchange: 600557.SS

Jiangsu Kanion Pharmaceutical Co.,Ltd.

CEO	Mr. Yongchun Yang
IPO Date	Sept. 18, 2002
Location	China
Headquarters	No. 58 Kangyuan Road
Employees	5,443
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Jiangsu Kanion Pharmaceutical Co.,Ltd. researches and develops, produces, and sells Chinese medicines. It offers medicines in the fields of gynecology, orthopedics, antiviral, cardio cerebrovascular, and other fields. The company was founded in 1975 and is based in Lianyungang, China.

Key trends

Past 5 years